GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » HeartBeam Inc (NAS:BEAT) » Definitions » ROE %

HeartBeam (HeartBeam) ROE % : -89.78% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is HeartBeam ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. HeartBeam's annualized net income for the quarter that ended in Dec. 2023 was $-15.52 Mil. HeartBeam's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $17.28 Mil. Therefore, HeartBeam's annualized ROE % for the quarter that ended in Dec. 2023 was -89.78%.

The historical rank and industry rank for HeartBeam's ROE % or its related term are showing as below:

BEAT' s ROE % Range Over the Past 10 Years
Min: -164.24   Med: -159.89   Max: -102.68
Current: -128.09

During the past 5 years, HeartBeam's highest ROE % was -102.68%. The lowest was -164.24%. And the median was -159.89%.

BEAT's ROE % is ranked worse than
91.97% of 610 companies
in the Healthcare Providers & Services industry
Industry Median: 4.115 vs BEAT: -128.09

HeartBeam ROE % Historical Data

The historical data trend for HeartBeam's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeartBeam ROE % Chart

HeartBeam Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
- - -102.68 -164.24 -159.89

HeartBeam Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -365.98 -2,184.03 -124.89 -69.94 -89.78

Competitive Comparison of HeartBeam's ROE %

For the Health Information Services subindustry, HeartBeam's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HeartBeam's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, HeartBeam's ROE % distribution charts can be found below:

* The bar in red indicates where HeartBeam's ROE % falls into.



HeartBeam ROE % Calculation

HeartBeam's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-14.639/( (2.374+15.937)/ 2 )
=-14.639/9.1555
=-159.89 %

HeartBeam's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-15.516/( (18.629+15.937)/ 2 )
=-15.516/17.283
=-89.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


HeartBeam  (NAS:BEAT) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-15.516/17.283
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-15.516 / 0)*(0 / 18.3895)*(18.3895 / 17.283)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.064
=ROA %*Equity Multiplier
=N/A %*1.064
=-89.78 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-15.516/17.283
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-15.516 / -15.516) * (-15.516 / -16.436) * (-16.436 / 0) * (0 / 18.3895) * (18.3895 / 17.283)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.944 * N/A % * 0 * 1.064
=-89.78 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


HeartBeam ROE % Related Terms

Thank you for viewing the detailed overview of HeartBeam's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


HeartBeam (HeartBeam) Business Description

Traded in Other Exchanges
N/A
Address
2118 Walsh Avenue, Suite 210, Santa Clara, CA, USA, 95050
HeartBeam Inc is a medical technology company primarily focusing on telemedicine solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. Its initial focus is providing diagnostic data to help physicians with the care management of patients with cardiovascular disease.
Executives
Urioste George De director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Kenneth Harry Persen officer: Chief Technology Officer 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Robert Paul Eno officer: President 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050
Michael R Jaff director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Mark E Strome 10 percent owner 100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Nelson Kenneth Warwick Iii director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Richard D Brounstein officer: Chief Financial Officer 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Alan Baumel officer: Chief Operating Officer 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 94050
Marga Ortigas-wedekind director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Richard M Ferrari director, officer: Exec Chm of the BOD 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Branislav Vajdic 10 percent owner, officer: Chief Executive Officer 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Willhem Elfrink director 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050
Jon Patrick Hunt officer: Chief Business Officer 2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050